{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:15:36Z","timestamp":1791274536701,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.neuropharm.2004.02.010","type":"journal-article","created":{"date-parts":[[2004,4,10]],"date-time":"2004-04-10T10:53:02Z","timestamp":1081594382000},"page":"1097-1104","source":"Crossref","is-referenced-by-count":98,"title":["Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist"],"prefix":"10.1016","volume":"46","author":[{"given":"Rafal M","family":"Kaminski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Rogawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2004.02.010_BIB1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/A:1022393604014","article-title":"Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate","volume":"28","author":"Angehagen","year":"2003","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0920-1211(03)00039-1","article-title":"Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures","volume":"54","author":"Angehagen","year":"2003","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0014-2999(95)00422-H","article-title":"Differentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant\/anticonvulsant activity","volume":"285","author":"Arnt","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(03)00265-5","article-title":"Cellular biology of epileptogenesis","volume":"2","author":"Avanzini","year":"2003","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00127893-200203000-00002","article-title":"New antiepileptic drugs","volume":"8","author":"Bazil","year":"2002","journal-title":"The Neurologist"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2174\/1381612024607108","article-title":"Kainate receptor agonists, antagonists and allosteric modulators","volume":"8","author":"Bleakman","year":"2002","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.2168579","article-title":"Molecular cloning and functional expression of glutamate receptor subunit genes","volume":"249","author":"Boulter","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(98)01286-3","article-title":"Kainate receptors: subunits, synaptic localization and function","volume":"20","author":"Chittajallu","year":"1999","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002508-200301000-00008","article-title":"The rationale and use of topiramate for treating neuropathic pain","volume":"19","author":"Chong","year":"2003","journal-title":"Clinical Journal of Pain"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/39315","article-title":"A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission","volume":"389","author":"Clarke","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB11","first-page":"8281","article-title":"Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6 and GluR7","volume":"19","author":"Cui","year":"1999","journal-title":"Journal ofNeuroscience"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00023210-200317060-00003","article-title":"Selection criteria for the clinical use of the newer antiepileptic drugs","volume":"17","author":"Deckers","year":"2003","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2004.02.010_BIB13","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/j.1528-1157.2000.tb06047.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB14","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/S0024-3205(01)01306-6","article-title":"Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration","volume":"69","author":"Edmonds","year":"2001","journal-title":"Life Sciences"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00004714-200304000-00011","article-title":"Antidepressant properties of anticonvulsant drugs for bipolar disorder","volume":"23","author":"Ernst","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0163-7258(96)00014-9","article-title":"New developments in the molecular pharmacology of \u03b1-amino-3-hydroxyisoxazole propionate and kainate receptors","volume":"70","author":"Fletcher","year":"1996","journal-title":"Pharmacology & Therapeutics"},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2004.02.010_BIB17","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1111\/j.1528-1157.1988.tb05795.x","article-title":"Progression and generalization of seizure discharge: anatomical and neurochemical substrates","volume":"29","author":"Gale","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB18","unstructured":"Ghetti, A., Plata-Salaman, C.R., Shank, R.P., Heinemann, S., 2001. Effects of topiramate on kainate receptors. Society for Neuroscience Abstracts 27, Program No. 871.1."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2004.02.010_BIB19","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","article-title":"Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons","volume":"41","author":"Gibbs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB20","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1523\/JNEUROSCI.23-18-07069.2003","article-title":"Selective antagonism of GluR5 kainate receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons","volume":"23","author":"Gryder","year":"2003","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB21","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1021\/jm50001a022","article-title":"Ibotenic acid analogues. Synthesis, molecular flexibility, and in vitro activity of agonists and antagonists at central glutamic acid receptors","volume":"28","author":"Lauridsen","year":"1985","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/33408","article-title":"Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice","volume":"392","author":"Mulle","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB24","series-title":"Antiepileptic Drugs","first-page":"3","article-title":"Principles of antiepileptic drug action","author":"Rogawski","year":"2002"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB25","first-page":"947","article-title":"AMPA receptors in epilepsy and as targets for antiepileptic drugs","volume":"79","author":"Rogawski","year":"1999","journal-title":"Advances in Neurology"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1749-6632.2003.tb07079.x","article-title":"GluR5 kainate receptors, seizures, and the amygdala","volume":"985","author":"Rogawski","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1528-1157.1994.tb02459.x","article-title":"Topiramate: preclinical evaluation of structurally novel anticonvulsant","volume":"35","author":"Shank","year":"1994","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2004.02.010_BIB28","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0165-0270(91)90028-X","article-title":"A slow intravenous infusion of N-methyl-DL-aspartate as a seizure model in the mouse","volume":"37","author":"Singh","year":"1991","journal-title":"Journal of Neuroscience Methods"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2004.02.010_BIB30","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1111\/j.1528-1157.2000.tb02171.x","article-title":"Topiramate blocks kainate-evoked cobalt influx into cultured neurons","volume":"41","author":"Skradski","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2004.02.010_BIB31","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1111\/j.1528-1157.2000.tb02172.x","article-title":"Effects of topiramate on kainate- and domoate-activated [14C]guanidinium ion flux through GluR6 channels in transfected BHK cells using Cytostar-T scintillating microplates","volume":"41","author":"Smith","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00001756-200104170-00033","article-title":"Topiramate promotes neurite outgrowth and recovery of function after nerve injury","volume":"12","author":"Smith-Swintosky","year":"2001","journal-title":"NeuroReport"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nn880","article-title":"Antagonists of GLUK5-containing kainate receptors prevent pilocarpine-induced limbic seizures","volume":"5","author":"Smolders","year":"2002","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB34","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/j.1460-2075.1992.tb05211.x","article-title":"A glutamate receptor channel with high affinity for domoate and kainate","volume":"11","author":"Sommer","year":"1992","journal-title":"EMBO Journal"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB35","first-page":"864","article-title":"Complex pharmacological properties of recombinant \u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes","volume":"42","author":"Stein","year":"1992","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(99)00512-9","article-title":"Resolution, absolute stereochemistry and molecular pharmacology of the enantiomers of ATPA","volume":"380","author":"Stensb\u00f8l","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB37","first-page":"1063","article-title":"Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants","volume":"265","author":"Steppuhn","year":"1993","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB38","series-title":"Antiepileptic Drugs","first-page":"85","article-title":"General principles: experimental selection, quantification, and evaluation of anticonvulsants","author":"Swinyard","year":"1989"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB39","first-page":"960","article-title":"Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate","volume":"288","author":"Taverna","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1526-4610.2002.02184.x","article-title":"Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis","volume":"42","author":"Von Seggern","year":"2002","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-1211(97)00045-4","article-title":"Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold","volume":"28","author":"White","year":"1997","journal-title":"Epilepsy Research"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2004.02.010_BIB42","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/jpet.103.058495","article-title":"Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), an orally active \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats","volume":"308","author":"Yamashita","year":"2004","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2004.02.010_BIB44","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","article-title":"Modulation of high-voltage-activated calcium channels in dentategranule cells by topiramate","volume":"41","author":"Zhang","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2004.02.010_BIB45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3940(97)00543-0","article-title":"Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells","volume":"231","author":"Zona","year":"1997","journal-title":"Neuroscience Letters"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804000486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804000486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:13:58Z","timestamp":1592954038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390804000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0028390804000486"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2004.02.010","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}